Jagsonpal Pharmaceuticals Limited is a long-standing player in the Indian pharmaceutical industry, known for its dedication to trust, credibility, and affordability. The company's primary vision is to nurture a healthier future for all, which is a core principle driving its overall goals and activities. It follows a patient-focused approach by placing special emphasis on individual requirements to meticulously design a portfolio of tailored solutions. The company has strategically built a strong presence in the therapeutic areas of gynaecology, orthopaedics, dermatology, and paediatrics. To ensure the highest quality standards, the company leverages an asset-light model by sourcing from top-tier Contract Manufacturing Organisations. With a sales force of over 975 individuals, the company has a nationwide reach to more than 1,50,000 prescribers.;

CEO/MD

Manish Gupta

Founded in

1978

NSE symbol

JAGSNPHARM

Shareholding pattern

Jun '25

Sep '25

Dec '25

Mar '26

Jun '26

Similar stocks

Stock	Mkt price (1D)	52 week performance	Market cap	P/E ratio	P/B ratio
Caplin Point LaboratoriesCAPLIPOINT	₹2,835.10 -32.30 (1.13%)	L H	21,555.40	31.79	6.4
PfizerPFIZER	₹4,000.80 -45.40 (1.12%)	L H	18,323.34	24.92	4.36
Jubilant PharmovaJUBLPHARMA	₹1,071.95 +8.10 (0.76%)	L H	17,111.21	48.69	2.41
Astrazeneca Pharma IndiaASTRAZEN	₹6,505.00 -86.00 (1.30%)	L H	16,294.63	96.06	18.67

ScoutQuest • 4 days ago

Jagsonpal Pharma signs deal to acquire Group Pharma's Wellness Portfolio for ₹46.7 Cr. Initial payment ₹23.7 Cr; completion by Nov 2026; no regulatory approvals needed.

BSE • 1 month ago

Jagsonpal Pharmaceuticals issued 27,950 equity shares under JPL ESOP 2022. Paid-up share capital increased to Rs. 13.19 crore; shares rank pari-passu with existing equity.

ScoutQuest • 2 months ago

Jagsonpal Pharma Q1 FY27 revenue grows 9% YoY to ₹822M, PAT rises 22% to ₹132M. Operating EBITDA up 21% YoY to ₹191M; margin expands to 23.2%; cash reserves at ₹1,700M post ₹400M buyback.

Livesquawk • 2 months ago

Jagsonpal Pharma's Q1 standalone net profit rose to ₹132M from ₹108M YoY. This reflects a notable growth in profitability for Jagsonpal Pharma.

ScoutQuest • 2 months ago

Jagsonpal Pharma acquires 85% stake in Aequitas Healthcare Pvt Ltd. Acquisition completed on July 17, 2026, marking strategic expansion.

ScoutQuest • 3 months ago

Jagsonpal Pharma acquires 69.77% stake in Aequitas Healthcare. Aequitas Healthcare becomes Jagsonpal Pharma's subsidiary post acquisition.

BSE • 3 months ago

Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare for INR 20.8 Cr. The acquisition marks Jagsonpal's strategic entry into the hospital segment, boosting its pharma presence.

ScoutQuest • 4 months ago

Jagsonpal Pharmaceuticals completed a buyback of 2 equity shares from May 8-14, 2026. Post-buyback advertisement was published on May 25, 2026, with BSE and public notified.

Marketsmojo • 5 months ago

Jagsonpal Pharma gained 2.66%, outperforming Sensex's 1.25% rise from 4-8 May 2026. Mixed financial results and valuation metrics led to a cautious investment rating upgrade.

Livemint • 5 months ago

FIIs increased stake in Shilpa Medicare, Marksans Pharma, and Jagsonpal Pharma in Q1 FY26, reflecting growing interest in Indian pharma. Shilpa Medicare expands in Latin America; Marksans gains FDA approvals; Jagsonpal focuses on women's health and financial discipline.

2026

4
Sep
Dividend
Ex date
₹4.00
per share

For each share you hold, you will receive ₹4.00

Dividend amount₹4.00 per share

Dividend TypeFinal

Ex Date4 Sep ‘26

Record Date4 Sep ‘26

Announcement date27 Apr ‘26

Jul

Quarterly Result

Release date

Check latest financial

4
May
Buyback
Ex date

Offer price₹250.00

Buyback window8 May ‘26 to 14 May ‘26

Ex date4 May ‘26

Record date4 May ‘26

Announcement date12 Mar ‘26

Buyback typeTender Offer

27
Apr
Dividend
Announced
₹4.00
per share

For each share you hold, you will receive ₹4.00

Dividend amount₹4.00 per share

Dividend TypeFinal

Ex Date4 Sep ‘26

Record Date4 Sep ‘26

Announcement date27 Apr ‘26

Apr

Annual Result

Release date

Check latest financial

12
Mar
Buyback
Announced

Offer price₹250.00

Buyback window8 May ‘26 to 14 May ‘26

Ex date4 May ‘26

Record date4 May ‘26

Announcement date12 Mar ‘26

Buyback typeTender Offer

Jan

Quarterly Result

Release date

Check latest financial

2025

Nov

Quarterly Result

Release date

Check latest financial

12
Sep
Dividend
Ex date
₹2.50
per share

For each share you hold, you will receive ₹2.50

Dividend amount₹2.50 per share

Dividend TypeFinal

Ex Date12 Sep ‘25

Record Date12 Sep ‘25

Announcement date6 May ‘25

Jul

Quarterly Result

Release date

Check latest financial

6
May
Dividend
Announced
₹2.50
per share

For each share you hold, you will receive ₹2.50

Dividend amount₹2.50 per share

Dividend TypeFinal

Ex Date12 Sep ‘25

Record Date12 Sep ‘25

Announcement date6 May ‘25

8
Jan
Split
Ex date
2:5
Ratio

For each share you hold, you will receive 2 shares with face value of ₹2.0 each

Split Ratio2:5

Ex date8 Jan ‘25

Record date8 Jan ‘25

Announcement date23 Oct ‘24

2024

23
Oct
Split
Announced
2:5
Ratio

For each share you hold, you will receive 2 shares with face value of ₹2.0 each

Split Ratio2:5

Ex date8 Jan ‘25

Record date8 Jan ‘25

Announcement date23 Oct ‘24

Events calendar

View upcoming events in other stocks

Home>Stocks>Jagsonpal Pharmaceuticals

Vaishnavi Tech Park, South Tower, 3rd FloorSarjapur Main Road, Bellandur, Bengaluru – 560103Karnataka

Download the App

Share Market

Indices

F&O

Mutual Funds

ETFs

Funds By Groww

Calculators

IPO

Miscellaneous

NIFTY Bank Options SBI Options Bajaj Finance Options Axis Bank Options Hindustan Unilever Options NIFTY Bank Futures Finnifty Futures ITC Futures ICICI Bank Futures Biocon Futures Indusind Bank Futures Crude Oil Mini Future Price Gold Petal Future Price Silver Micro Future Price Nickel Future Price Natural Gas Mini MCX Option Chain Copper MCX Option Chain

NIFTY 50 Options HDFC Bank Options Wipro Options DLF Options REC Options Yes Bank Futures Zomato Futures Ashok Leyland Futures HDFC Bank Futures UPL Futures Adani Enterprises Futures Gold Future Price Natural Gas Future Price Zinc Future Price Gold MCX Option Chain Gold Mini MCX Option Chain Commodities Expiry Calendar

Bse Sensex Options Tata Steel Options NTPC Options Bajaj Auto Options Indusind Bank Options Tata Motors Futures Infosys Futures Asian Paints Futures Lupin Futures Cipla Futures IDFC First Bank Futures Gold Mini Future Price Natural Gas Mini Future Price Copper Future Price Crude Oil MCX Option Chain Silver MCX Option Chain

Finnifty Options Infosys Options Asian Paints Options Coal India Options Ashok Leyland Options Tata Steel Futures BSE Sensex Futures Wipro Futures DLF Futures Bajaj Finance Futures Piramal Enterprises Futures Gold Ten Future Price Silver Future Price Aluminium Future Price Crude Oil Mini MCX Option Chain Silver Mini MCX Option Chain

Tata Motors Options ITC Options ICICI Bank Options Adani Enterprises Options NIFTY 50 Futures Coal India Futures Axis Bank Futures Vedanta Futures Reliance Industries Futures Hindustan Copper Futures Crude Oil Future Price Gold Guinea Future Price Silver Mini Future Price Electricity Future Price Natural Gas MCX Option Chain Zinc MCX Option Chain

MF Screener Debt Mutual Funds Best Multicap Mutual funds Best Contra Mutual funds Best Conservative Hybrid Mutual funds SBI Contra Fund Nippon India Nifty 500 Momentum 50 Index Fund HDFC Balanced Advantage Fund Quant Mid Cap Fund Bank of India Small Cap Fund Quant Multi Asset Fund Nippon India TATA Bandhan Edelweiss HSBC Union Quantum Shriram

Compare Mutual Funds Best Debt Mutual funds Best Large Cap Mutual funds Best Value Oriented Mutual funds Parag Parikh Flexi Cap Fund HDFC Mid Cap Opportunities Fund Motilal Oswal Nifty India Defence Index Fund ICICI Prudential India Opportunities Fund Kotak Small Cap Fund Canara Robeco Bluechip Equity Fund GrowwMF Motilal Oswal Aditya Birla Axis Bank of India Bajaj Finserv Helios ITI Trust

MF Knowledge Centre Best Equity Mutual funds Best Small Cap Mutual funds Best Arbitrage Mutual funds Motilal Oswal Midcap Fund SBI Small Cap Fund HDFC Small Cap Fund Kotak Multicap Fund ICICI Prudential Infrastructure Fund Bandhan Nifty Alpha 50 Index Fund SBI Quant Mirae Asset DSP Baroda BNP Paribas Mahindra Manulife Sundaram Samco Taurus

Mutual Fund Houses Best Hybrid Mutual funds Best ELSS Mutual funds Best Dividend Yield Mutual funds Nippon India Small Cap Fund HDFC Flexi Cap Fund Tata Small Cap Fund Tata Ethical Fund Mirae Asset ELSS Tax Saver Fund Quant Infrastructure Fund HDFC PPFAS UTI Kotak Mahindra Zerodha Invesco Navi PGIM

Mutual Funds Categories Best MidCap Mutual funds Best Sectoral Mutual funds Best Aggressive Hybrid Mutual funds Quant Small Cap Fund SBI Magnum Children's Benefit Fund UTI Nifty 50 Index Fund JM Flexicap Fund HSBC Small Cap Fund Franklin India Multi Cap Fund ICICI Prudential LIC Canara Robeco Whiteoak Franklin Templeton NJ JM 360 One

International Silver Midcap Liquid

Debt Index Bank Nifty Nifty IT

Equity Nifty 50 Nifty Metal Nifty Auto

Commodity Nifty Next 50 Healthcare Groww

Gold Sensex Defence

What is IPO?How to Apply for an IPO

Open IPOs What is Grey Market Premium?

Upcoming IPOs Mainboard IPOs

Closed IPOs SME IPOs

IPO Subscription Status IPO Allotment Status

Others:

NSEBSEMCXTerms and ConditionsPolicies and ProceduresRegulatory & Other InfoPrivacy PolicyDisclosureSMART ODRDownload FormsInformation Security PracticesInvestor Charter and GrievanceBug BountyGroww Pay - Terms of useGroww Pay - Privacy policyGroww IFSC

Mutual Funds:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others

Stocks:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others

About Groww

Groww is India's largest Stock Broker with more than 1.4 crore active customers where users can find their investment solutions pertaining to mutual funds, stocks, US Stocks, ETFs, IPO, and F&Os, to invest their money without hassles.

Groww objectively evaluates stocks and mutual funds and does not advise or recommend any stocks, mutual funds or portfolios. Investors shall invest at their own discretion, will and consent. Groww, at any time, does not guarantee fixed returns on the capital invested.

Groww helps investors -

· By providing 100% paperless online free Demat and trading account opening

· By providing an objective evaluation of products available on the platform

· By being transparent about fees and charges involved while investing in a product

· By offering decision-making assistance by providing technical analysis with advanced charts, well-designed line & candlestick charts that indicate share price movements, and market indices, along with more details about all registered and listed companies

SECURE TRANSACTIONS ON GROWW

All transactions on Groww are safe and secure. Users can invest through SIP or Lumpsum using Netbanking through all supported banks. It uses BSE Star MF (with Member code 11724) as transaction platform.

TRADE AND INVEST SECURELY WITH GROWW

Stocks, Mutual fund investments, F&Os, etc., are very popular with individual investors because of their numerous benefits. On Groww, an investor can -

- Invest in Nifty 50 (NSE) & Sensex (BSE) listed stocks

- Diversify across multiple stocks and other instruments

- Start SIP with any amount (as low as Rs. 500)

- Switch regular funds to direct funds

- Start automated monthly investments (SIP), and benefit from many more features

All type of mutual funds are available on Groww.

INVESTING IN MUTUAL FUND PORTFOLIOS

Portfolio is collection of mutual funds designed to meet your investment goals. Investing in mutual fund portfolios helps you in diversifying your investments and reduces the risk. Portfolios also help you in assigning an investment goals and make it easy for you to save for and achieve your goals. You can create a portfolio yourself or ask an expert to build it for you.

ATTENTION INVESTORS

1. For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors.

2. For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors.

3. KYC is a one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

4. If you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non allotment the funds will remain in your bank account.

· Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.

· Awareness regarding guidelines on Margin collection

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Issued in the interest of Investors

DISCLAIMER

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) (CIN: U65100KA2016PTC092879) is a member of NSE & BSE & MCX with SEBI Registration no: INZ000301838, Depository Participant of CDSL Depository with SEBI Registration no: IN-DP-417-2019 and Mutual Fund distributor with AMFI Registration No: ARN-111686. Registered office and Correspondence office - Vaishnavi Tech Park, South Tower, 3rd floor, Sarjapur Main Road, Bellandur, Bengaluru – 560103, Karnataka. For any grievances related to Stock Broking/DP, please write to [email protected] , please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Unless otherwise specified, all returns, expense ratio, NAV, etc are historical and for illustrative purposes only. Future will vary greatly and depends on personal and market circumstances. The information provided by our blog is educational only and is not investment or tax advice.

Investment in Securities Market are subject to market risks, read all the related documents carefully before investing

Mutual fund investments are subject to market risks. Please read all scheme related documents carefully before investing. Past performance of the schemes is neither an indicator nor a guarantee of future performance.

India's largest Stock Broker by active users on NSE as of June 30, 2025. Refer: NSE's Arbitration status

Terms and conditions of the website/app are applicable. Privacy policy of the website is applicable.

Jagsonpal Pharmaceuticals

Performance

Fundamentals

Financial performance

About

Shareholding pattern

Similar stocks

4SepDividendEx date₹4.00per share

4MayBuybackEx date

27AprDividendAnnounced₹4.00per share

12MarBuybackAnnounced

12SepDividendEx date₹2.50per share

6MayDividendAnnounced₹2.50per share

8JanSplitEx date2:5Ratio

23OctSplitAnnounced2:5Ratio

About Groww

4
Sep
Dividend
Ex date
₹4.00
per share

4
May
Buyback
Ex date

27
Apr
Dividend
Announced
₹4.00
per share

12
Mar
Buyback
Announced

12
Sep
Dividend
Ex date
₹2.50
per share

6
May
Dividend
Announced
₹2.50
per share

8
Jan
Split
Ex date
2:5
Ratio

23
Oct
Split
Announced
2:5
Ratio